Zydus Lifesciences Limited
NSE: ZYDUSLIFE BSE: ZYDUSLIFE
NSE
960.15
4.45 (0.47%)
Prev Close
955.7
Open Price
960
Volume
810,089
Today Low / High
948.85 / 962.5
52 WK Low / High
795 / 1324.3
Range
912 - 1,008
BSE
960.00
4.40 (0.46%)
Prev Close
955.6
Open Price
963.65
Volume
24,060
Today Low / High
949.25 / 963.65
52 WK Low / High
797.05 / 1323.9
Range
912 - 1,008
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 960.15 (target range: 912 - 1,008), reflecting a change of 4.45 (0.46563%). On the BSE, it is listed at 960 (target range: 912 - 1,008), showing a change of 4.4 (0.46044%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
06 Jun
960.00
0.02%
05 Jun
933.00
2.43%
04 Jun
934.95
-0.37%
03 Jun
930.00
-0.39%
02 Jun
933.95
-0.64%
30 May
929.00
0.11%
29 May
932.00
-0.78%
28 May
925.00
0.06%
27 May
916.60
0.16%
26 May
914.00
-0.13%
23 May
904.00
0.51%
22 May
890.00
1.51%
21 May
879.00
1.21%
20 May
917.50
-3.73%
19 May
906.00
0.58%
16 May
902.00
0.08%
15 May
903.80
0.10%
14 May
903.45
0.01%
13 May
884.85
1.92%
12 May
881.00
0.44%
09 May
859.00
2.29%
Zydus Lifesciences Limited Graph
Zydus Lifesciences Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Zydus Lifesciences Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 960.15, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 960.00 | 969.60 | 872.64 - 1,066.56 |
| 979.20 | 783.36 - 1,175.04 | ||
| 988.80 | 692.16 - 1,285.44 | ||
| Bearish Scenario | 960.00 | 950.40 | 855.36 - 1,045.44 |
| 940.80 | 752.64 - 1,128.96 | ||
| 931.20 | 651.84 - 1,210.56 |
Overview of Zydus Lifesciences Limited
ISIN
INE010B01027
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
1,461,866
Market Cap
966,131,734,500
Last Dividend
3
Official Website
IPO Date
2002-07-01
DCF Diff
-295.35
DCF
1,255
Financial Ratios Every Investor Needs
Stock Dividend of ZYDUSLIFE
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-25 | July 25, 25 | 11 | 11 | 2025-07-25 | 2025-09-11 | |
| 2024-07-26 | July 26, 24 | 3 | 3 | 2024-07-26 | 2024-09-08 | |
| 2023-07-27 | July 27, 23 | 6 | 6 | 2023-07-28 | 2023-09-10 | |
| 2022-07-28 | July 28, 22 | 2.5 | 2.5 | 2022-07-29 | 2022-08-16 | |
| 2021-07-28 | July 28, 21 | 3.5 | 3.5 | 2021-07-29 | 2021-09-10 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 19,547.40 Cr | 10,622.50 Cr | 8,924.90 Cr | 0.4566 | 1,312.50 Cr | 517.60 Cr | 4,539.50 Cr | 3,859.50 Cr | 38.14 | 5,622.20 Cr | 0.1974 |
| 2023-03-31 | 16,877.80 Cr | 6,310.10 Cr | 10,567.70 Cr | 0.6261 | 135.80 Cr | 582.90 Cr | 2,852.80 Cr | 1,960.30 Cr | 19.30 | 3,442.20 Cr | 0.1161 |
| 2022-03-31 | 14,827.60 Cr | 5,818.90 Cr | 9,008.70 Cr | 0.6076 | 114.60 Cr | 428.10 Cr | 2,474.10 Cr | 4,487.30 Cr | 17.65 | 3,671.00 Cr | 0.3026 |
| 2021-03-31 | 14,821.50 Cr | 5,480.00 Cr | 9,341.50 Cr | 0.6303 | 118.40 Cr | 472.10 Cr | 2,735.60 Cr | 2,133.60 Cr | 20.84 | 3,232.90 Cr | 0.1440 |
| 2020-03-31 | 13,812.10 Cr | 5,149.40 Cr | 8,662.70 Cr | 0.6272 | 89.70 Cr | 543.90 Cr | 2,101.80 Cr | 1,176.60 Cr | 11.49 | 2,524.50 Cr | 0.0852 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 413.00 Cr | 29,280.80 Cr | 7,179.20 Cr | 19,829.5000 Cr | 804.20 Cr | 391.20 Cr | 3,441.90 Cr | 6,914.80 Cr | 0.00 Cr | 0.00 Cr | 11.20 Cr | 5,341.9000 Cr |
| 2023-03-31 | 487.80 Cr | 25,756.40 Cr | 6,068.10 Cr | 17,515.8000 Cr | 1,194.90 Cr | 707.10 Cr | 3,413.30 Cr | 6,826.70 Cr | 1,960.10 Cr | 29.50 Cr | 927.30 Cr | 5,530.7000 Cr |
| 2022-03-31 | 657.80 Cr | 27,795.40 Cr | 8,741.60 Cr | 16,999.6000 Cr | 4,220.90 Cr | 3,563.10 Cr | 3,719.40 Cr | 6,422.60 Cr | 1,824.40 Cr | 28.70 Cr | 934.80 Cr | 7,839.4000 Cr |
| 2021-03-31 | 665.20 Cr | 23,884.70 Cr | 8,955.10 Cr | 12,992.3000 Cr | 4,607.60 Cr | 3,942.40 Cr | 3,236.20 Cr | 6,333.20 Cr | 1,648.30 Cr | 22.70 Cr | 631.20 Cr | 7,861.3000 Cr |
| 2020-03-31 | 845.30 Cr | 23,686.60 Cr | 11,976.20 Cr | 10,375.7000 Cr | 8,013.80 Cr | 7,168.50 Cr | 2,789.00 Cr | 6,193.70 Cr | 1,437.30 Cr | 7.60 Cr | 552.20 Cr | 8,269.4000 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 3,227.9000 Cr | -1,475.2000 Cr | -1,810.4000 Cr | 2,321.3000 Cr | -74.8000 Cr | 413.0000 Cr | -906.6000 Cr | 3,859.5000 Cr | -392.9000 Cr | -621.0000 Cr | -2.0000 Cr |
| 2023-03-31 | 2,688.8000 Cr | 1,171.2000 Cr | -4,400.4000 Cr | 1,657.9000 Cr | -533.8000 Cr | 573.1000 Cr | -1,030.9000 Cr | 2,582.7000 Cr | -3,147.2000 Cr | -267.1000 Cr | 440.7000 Cr |
| 2022-03-31 | 2,104.1000 Cr | 1,154.4000 Cr | -868.3000 Cr | 901.5000 Cr | 2,372.9000 Cr | 3,460.1000 Cr | -1,202.6000 Cr | 5,232.3000 Cr | -383.7000 Cr | -372.2000 Cr | -525.5000 Cr |
| 2021-03-31 | 3,293.0000 Cr | -722.5000 Cr | -2,548.9000 Cr | 2,439.0000 Cr | -90.5000 Cr | 1,087.2000 Cr | -854.0000 Cr | 2,284.8000 Cr | -3,342.7000 Cr | -1.5000 Cr | -479.7000 Cr |
| 2020-03-31 | 2,505.4000 Cr | -1,012.3000 Cr | -1,094.2000 Cr | 1,601.3000 Cr | 398.9000 Cr | 1,177.7000 Cr | -904.1000 Cr | 1,495.4000 Cr | -348.9000 Cr | -856.9000 Cr | -101.0000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 5,123.50 Cr | 1,583.40 Cr | 3,540.10 Cr | 0.6910 | 976.00 Cr | 1,023.50 Cr | 10.17 | 1,445.10 Cr | 0.1998 |
| 2024-09-30 | 5,113.60 Cr | 1,471.40 Cr | 3,642.20 Cr | 0.7123 | 1,182.40 Cr | 911.20 Cr | 9.06 | 1,529.60 Cr | 0.1782 |
| 2024-06-30 | 6,207.50 Cr | 2,684.90 Cr | 3,522.60 Cr | 0.5675 | 1,893.90 Cr | 1,419.90 Cr | 14.11 | 2,147.20 Cr | 0.2287 |
| 2024-03-31 | 5,366.40 Cr | 1,611.50 Cr | 3,754.90 Cr | 0.6997 | 1,581.60 Cr | 1,182.30 Cr | 11.45 | 1,786.90 Cr | 0.2203 |
| 2023-12-31 | 4,343.70 Cr | 1,468.50 Cr | 2,875.20 Cr | 0.6619 | 945.30 Cr | 789.60 Cr | 7.80 | 1,140.10 Cr | 0.1818 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 1,061.40 Cr | 1,933.70 Cr | 2,995.10 Cr | 0.00 Cr | 3,716.90 Cr | 12,156.90 Cr | 7,153.10 Cr | 31,445.90 Cr | 7,291.30 Cr |
| 2024-03-31 | 413.00 Cr | 252.50 Cr | 1,357.60 Cr | 5,220.20 Cr | 3,441.90 Cr | 11,419.80 Cr | 6,914.80 Cr | 29,280.80 Cr | 7,179.20 Cr |
| 2023-12-31 | -1,519.50 Cr | 3,039.00 Cr | 1,519.50 Cr | 0.00 Cr | 0.00 Cr | 1,519.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 346.30 Cr | 1,671.20 Cr | 2,017.50 Cr | 3,915.20 Cr | 3,303.90 Cr | 9,934.80 Cr | 6,936.60 Cr | 25,879.40 Cr | 4,938.50 Cr |
| 2023-06-30 | -1,192.40 Cr | 2,384.80 Cr | 1,192.40 Cr | 0.00 Cr | 0.00 Cr | 1,192.40 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1,182.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 789.60 Cr | 389.60 Cr | 0.00 Cr | 0.00 Cr | 389.60 Cr | 1,296.70 Cr | 907.10 Cr | 0.00 Cr | 389.60 Cr |
| 2023-09-30 | 800.70 Cr | 368.40 Cr | 0.00 Cr | 0.00 Cr | 368.40 Cr | 907.10 Cr | 538.70 Cr | 0.00 Cr | 368.40 Cr |
| 2023-06-30 | 1,086.90 Cr | 359.60 Cr | 0.00 Cr | 0.00 Cr | 359.60 Cr | 852.20 Cr | 492.60 Cr | 0.00 Cr | 359.60 Cr |
| 2023-03-31 | 296.60 Cr | 357.20 Cr | 0.00 Cr | 0.00 Cr | 357.20 Cr | 492.60 Cr | 135.40 Cr | 0.00 Cr | 357.20 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2015-10-06 | October 06, 15 | 5:1 |
| 2010-04-05 | April 05, 10 | 3:2 |
| 2006-08-30 | August 30, 06 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,679.20 | ₹4,028,870,976,000.00 | ₹2,500,031.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,544.50 | ₹1,737,361,870,500.00 | ₹361,018.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,320.90 | ₹1,100,458,988,118.00 | ₹2,158,463.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,154.30 | ₹1,067,557,063,500.00 | ₹86,576.00 |
| Mankind Pharma Limited | MANKIND | ₹2,352.40 | ₹970,767,378,020.00 | ₹353,197.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹960.15 | ₹966,131,734,500.00 | ₹810,089.00 |
| Lupin Limited | LUPIN | ₹1,999.60 | ₹913,207,322,000.00 | ₹1,289,535.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,161.10 | ₹674,369,202,200.00 | ₹392,642.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,862.50 | ₹581,384,812,500.00 | ₹181,782.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,590.20 | ₹448,756,030,200.00 | ₹940,265.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,055.10 | ₹403,646,450,141.00 | ₹209,681.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,370.90 | ₹347,802,813,600.00 | ₹594,702.00 |
| Laurus Labs Limited | LAURUSLABS | ₹642.05 | ₹346,227,388,650.00 | ₹1,658,718.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,571.30 | ₹321,186,225,600.00 | ₹84,218.00 |
| Piramal Enterprises Limited | PEL | ₹1,173.70 | ₹266,051,968,600.00 | ₹1,087,297.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,702.30 | ₹265,322,180,300.00 | ₹62,791.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,790.00 | ₹244,750,000,000.00 | ₹123,199.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,505.40 | ₹244,595,886,600.00 | ₹803,276.00 |
| Eris Lifesciences Limited | ERIS | ₹1,638.30 | ₹223,111,885,500.00 | ₹55,563.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹987.60 | ₹194,125,618,800.00 | ₹40,498.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,140.00 | ₹181,580,340,000.00 | ₹116,733.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,030.00 | ₹167,173,597,000.00 | ₹539,376.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,093.30 | ₹159,115,291,610.00 | ₹64,315.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹858.30 | ₹153,730,113,000.00 | ₹354,578.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹529.95 | ₹128,536,192,800.00 | ₹485,798.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,560.50 | ₹92,300,963,700.00 | ₹8,096.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹914.45 | ₹89,424,888,505.00 | ₹310,698.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹909.25 | ₹82,409,528,235.00 | ₹242,116.00 |
| Strides Pharma Science Limited | STAR | ₹782.30 | ₹72,098,880,210.00 | ₹430,298.00 |
| FDC Limited | FDC | ₹429.20 | ₹69,878,052,000.00 | ₹308,089.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹165.55 | ₹53,724,617,100.00 | ₹2,347,837.00 |
| Innova Captab Limited | INNOVACAP | ₹889.10 | ₹50,878,685,263.00 | ₹72,505.00 |
| Suven Life Sciences Limited | SUVEN | ₹221.19 | ₹48,235,788,060.00 | ₹1,475,325.00 |
| Sequent Scientific Limited | SEQUENT | ₹187.85 | ₹47,019,230,700.00 | ₹442,806.00 |
| Hikal Limited | HIKAL | ₹372.35 | ₹45,911,127,350.00 | ₹154,610.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹462.15 | ₹42,180,430,500.00 | ₹112,178.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹592.90 | ₹41,743,598,820.00 | ₹18,878.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹368.10 | ₹36,912,331,800.00 | ₹50,918.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹718.15 | ₹36,423,921,665.00 | ₹149,821.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,141.70 | ₹35,421,576,300.00 | ₹12,390.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹64.12 | ₹35,134,810,480.00 | ₹2,840,731.00 |
| Alembic Limited | ALEMBICLTD | ₹112.07 | ₹28,777,558,628.00 | ₹591,652.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹88.74 | ₹26,047,585,980.00 | ₹1,118,303.00 |
| Indoco Remedies Limited | INDOCO | ₹275.10 | ₹25,377,397,290.00 | ₹25,198.00 |
Key Executives
Company Secretary & Compliance Officer
Mr. Dhaval Narendra Soni
Gender: male
Year Born:
Chief Financial Officer
Mr. Nitinkumar Dalsukhray Parekh
Gender: male
Year Born:
Chief Operating Officer & Executive Director
Dr. Ganesh Narayan Nayak
Gender: Not Specified
Year Born: 1955
President & Chief Executive Officer of America
Mr. Punit Patel
Gender: male
Year Born:
Head of Investor Relations
Mr. Arvind Bothra
Gender: male
Year Born:
President of Parenteral Operations
Mr. Vikram Shukla
Gender: male
Year Born: 1974
President of Finance
Mr. Tushar Dhansukh Shroff
Gender: male
Year Born:
MD & Executive Director
Dr. Sharvil Pankajbhai Patel
Gender: Not Specified
Year Born: 1979
FAQs about Zydus Lifesciences Limited
Who is the CEO of the company?
The CEO is Mr. Punit Patel.
What is the current market price of the stock?
The current price is ₹960.15.
What is the 52-week price range?
The range is ₹795-1324.3.
What is the market capitalization of the company?
The market capitalization is ₹96,613.17 crores.
What is the dividend yield?
The dividend yield is 0.31%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 21.30.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Zydus Lifesciences Limited (ISIN: INE010B01027) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹96,613.17 crores and an average daily volume of 1,461,866 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹3.